Dr. Zhao is currently the Chairman of Department of Neurology in Xijing Hospital and the Vice President of Xijing Brain Hospital of the Fourth Military Medical University. He graduated from the Fourth Military Medical University in 1983, and continued his study of neuroinfection and cerebrospinal fluid cytology in Ghent University School of Medicine in 1992. From 1998 to 2002, he engaged in the research of cerebrovascular disease and neuroprotective drugs in Kingston General Hospital of Queen's University in Canada.
Dementia; Dizzy; Headache; Cerebrovascular Disease and Parkinson's Disease
Dr. Kyritsis received his MD in 1978 and DSc degree in 1988 from the Medical School of the National and Kapodistrian University of Athens Greece. Subsequently, he had basic research training at the National Institutes of Health, USA, from 1981 to 1986 and residency in Neurology at the University of Wisconsin University Hospital, Madison, Wisconsin, USA. Subsequently he did a clinical fellowship in Neuro-oncology at the Department of Neuro-Oncology at the University of Texas M. D. Anderson Cancer Center in Houston, Texas, and then served as Assistant and Associate Professor at the same department from 1992 to 1999. In 1999, he moved to the Department of Neurology at the University of Ioannina as Professor and Chairman of Neurology.
Neurogenic inflammation; Papilledema; Radiculopathy; Cerebrospinal fluid and Radiotherapy
Use of various functional, morphologic brain imaging techniques (MRI, fMRI, SPECT, PET) in the diagnosis and evaluation of progression of neurodegenerative disorders, i.e. Parkinson’s disease in combination with various simple instrumental tools; Performance of neuropharmacological trials with putative neuroprotective or neuroregnerative compounds in neurodegenerative disease at least partially in close cooperation with the pharmaceutical industry; Investigations of neuroophthalmologic changes in neurodegnerative disorders and the impact of dopaminergic compounds on visual function; Studies on the pathogenesis of Parkinson’s disease, dystonia, Huntington’s disease, vascular brain disease and dementia with search for genetic, metabolic and environmental biomarkers and risk factors for neurodegenerative diseases; Performance of epidemiologic, pharmacokinetic and pharmacologic trials on the efficacy of antiparkinsonian agents; Research on neuropsychological changes in neurodegenerative diseases; Development and use of instrumental procedures and various reaction time paradigms for the evaluation of drug response in Parkinson’s disease; Research on levodopa induced vascular risk factors in neurodegenerative diseases with specific evaluation of genetic polymorphisms of drug metabolizing enzymes; Evaluation of the clinical efficacy of intrathecally administered steroid preparation in the treatment of progressive multiple sclerosis with predominant spinal symptoms; Studies on fine motor skills and control in Parkinson‘s disease and related movement disorders
Dr. Dale Ding is a neurosurgeon in Charlottesville, Virginia and is affiliated with University of Virginia Medical Center. He received his medical degree from Duke University School of Medicine and has been in practice between 6-10 years. He is one of 14 doctors at University of Virginia Medical Center who specialize in Neurological Surgery.
Cerebral artery aneurysm; Acute ischemic stroke; Aneurysmal subarachnoid hemorrhage; Cerebral vasospasm and delayed cerebral ischemia
Internationally known for his work on Alzheimer’s disease, he is a Professor of Pharmacology, Microbiology and Immunology at Temple University, Lewis Katz School of Medicine. He has authored over 235 peer-reviewed articles and 22 chapters in thematic books. He has received many awards for his research accomplishments including the Biomedicine Investigator Award for Excellence in Scientific Research, Irvine H. Page Award for Medical Research, Neurosciences Education and Research Award, and The Zenith Award from the Alzheimer’s Association.
Oxidative neurobiology;Alzheimer’s disease ;Parkinson’sdisease;Frontotemporal dementia;Neurodegeneration
1. European Bristol-Myer-Squibb Post Doctoral Fellowship.
2. Italian Research Council Fellowship.
3. Investigator Award for Excellence in Scientific Research.
4. American Federation for Aging Research.
5. Irvine H. Page Research Award.
6. Neurosciences Education and Research Foundation Award.
7. Zenith Fellow of the Alzheimer’s Association.
8. Dorothy Dillon Eweson Lectureship.
He has published a total of 235 peer-reviewed articles.
Neuropsychiatry of Alzheimer's disease and Mild Cognitive Impairment Neuropsychiatry of Parkinson's disease;Neuropsychiatry of stroke; Cognitive deficits and associated brain structural abnormalities of schizophrenia; Mechanisms of brain aging and subclinical neuropsychiatry phenomenology in healthy people
Phosphorylation of target proteins; Morphology; Acetaldehyde and Salsolinol
Acoustic neuromas; Aneurysm surgery; Arteriovenous malformation; Brain tumors; Carotid disease; Meningiomas; Neurovascular surgery; Pituitary tumors/disease; Skull base surgery; Transsphenoidal pituitary surgery; Vascular malformations; Medullar stimulation for pain; Trigeminal pain; Celiac pain; Spasticity and Cervical degenerative diseases
Dr. Ajami Experienced immunologist and molecular biologist with expertise in neuroinflammation, signaling and cancer biology. Highly knowledgeable of microglia and its biology in neurological diseases as evidenced by two first-author-papers in Nature Neuroscience journal cited and highly regarded over 1200 times. She Innovative immunologist with demonstrated scientific expertise in cutting-edge technology such as mass cytometry (CyToF), confocal and fluorescence microscopy, live cell imaging, flow cytometry, and in vivo rodent techniques. Deep knowledge and understanding of pathology in various neurological disorders such as Multiple Sclerosis, Huntington disease, Amyotrophic Lateral Sclerosis (ALS) and spinal cord injury. 18+ years experience in cultivating novel ideas, independent experimental planning and design, execution, evaluation, and presentation of data.
Neuroinflammation; Multiple sclerosis and Microglia
Clinical neurology and Neurosurgery
Immunogenetics; Demyelinating diseases; DNA extraction; PCR; Gel electrophoresis and HLA-DR-DQ genotyping; Neuro-ICU; Transcranial doppler; Diffussion-Perfusion MRI; Thrombolysis with r-TPA; Multiple sclerosis; Genetics of autoimmune diseases; Psychiatry and Internal medicine
Vascular biology; Molecular biology; Pharmacology; Neurosurgery and Clarification of the molecular mechanism underlying the pathogenesis of intracranial aneurysm
Dr. Peggy Bosch received her MA-degree in Clinical Psychology (2002) from the Radboud University Nijmegen (Nijmegen, the Netherlands) and her PhD-degree in Psychology (2015) also from the Radboud University Nijmegen. She currently works as a postdoc at the Radboud University Nijmegen and as a clinical psychologist at the LVR-Klinik Bedburg-Hau (Kleve, Germany). Peggy is Head of the psychiatric research institute of the LVR-Klinik Bedburg-Hau (Kleve, Germany), conducting mainly research on schizophrenia, depression, and sleep disorders.
Schizophrenia, Depression, Sleep disorders, Trauma, fMRI, TMS
1. The development of a human (un)conscious brain information processing theory in which physics and neuroscience can be unified. [see also the Nature website: http://www.nature.com/nature/report/index.html?comment=68881&doi=10.1038/538036a]
2. Dr. Bosch is one of the leading Discussants of the possibilities and risks of brain stimulation. [see also Science: Science. 2014 Dec 12;346(6215):1307. doi: 10.1126/science.346.6215.1307-a
Neurodegeneration and developmental disease; Neuroimmunology; Peripheral neurology and myopathy; The treatment of osteoarticular diseases by botox; Arthroscopy technique; Artificial joint replacement and muscle weakness; Muscle atrophy; Numbness nerve muscle and Nerve immunity myopathy
Neurobiology; Modulation of the glutamate-nitric oxide-cGMP and the learning ability by extracellular cGMP in cerebellum
Dr. Hugh Chan received his PhD from Imperial College London in 2010. He is currently a postdoctoral fellow at the Neurosciences Department of Lerner Research Institute of Cleveland Clinic. His current research focuses on the rehabilitation and repair in experimental stroke and traumatic brain injury models.
Alzheimer’s disease; Parkinson’s disease; Stroke; Traumatic brain injury
Dr. Hugh Chan has rewarded the inaugural Best Abstract Awards in 2015; He has rewarded 2nd position of Young Scientists Presentation (Imperial College London) in 2008; He has rewarded 3rd position of Young Scientists Presentation (Imperial College London) in 2007; During 2005-2008, he has rewarded Dorothy Hodgkin Postgraduate Award (UK), and during 2002- 2004, he has rewarded Postgraduate fellowship.
Dr. Chang is the Lab Chief for the Laboratory of Neurodegenerative Diseases in the School of Biomedical Sciences, member in The State Key Laboratory of Brain and Cognitive Sciences. Dr. Chang is also the Founder and Secretary of HKU Alzheimer’s Disease Research Network. He organizes International Alzheimer’s Disease Conference every year since 2000. Dr. Chang received his undergraduate training in Biochemistry in Hong Kong learning neurochemistry. He then learnt neuroimmunology, neuroanatomy and neurochemistry for his MPhil study. He moved to University of Munich, Institute for Surgical Research in Germany for his PhD working on clinical neuroscience and neurophysiology. Afterwards, he moved to National Institutes of Health for his postdoctoral training working on molecular neuroscience and neuropharmacology. Dr. Chang’s research interest is pathophysiological changes of Alzheimer’s disease (AD) and the risk factors (depression, cigarette smoking, systemic inflammation, and environmental toxins) leading to AD. He has published over 120 peer-reviewed papers and 14 book chapters in these areas. His h-index is 42 by Google-Scholar and 34 by Scopus. Dr. Chang is in the Scientific Advisory Board of International AD/PD Symposium, Scientific Review Committee in Alzheimer Association. He is the handling associate editor in Journal of Alzheimer’s Disease, and Senior Editor for Journal of Neuroimmune Pharmacology. He is the member of editorial board of more than 20 different journals. He is also a grant reviewer for many different grant agencies/Foundations. Dr. Chang is now the Editor-in-Chief of the ‘American Journal of Alzheimer’s Disease and Other Dementias, which has 20 years history in Alzheimer’s disease field.
Alzheimer’s disease; Parkinson’s disease; Glaucoma; Depression; Systemic inflammation; Herbal medicine
Dr. Chang has published over 120 peer-reviewed papers and 14 book chapters on pathophysiological changes of Alzheimer’s disease (AD) and the risk factors (depression, cigarette smoking, systemic inflammation, and environmental toxins) leading to AD.
Aswin is an NIHR Academic Clinical Fellow (Imperial College London) and Neurosurgical Trainee (North Thames Rotation). He is also the chair of the British Neurosurgical Trainee Research Collaborative. His current research focuses on the translational potential of therapies for spinal cord injury and regeneration under the supervision of Prof Simone di Giovanni. Aswin trained in Medicine at the University of Cambridge (MA) and University of Oxford (BMBCh) before taking up an academic foundation post at the University of Cambridge. His research focussed on neurotrauma, in particular the surgical and medical management of chronic subdural haematoma, under the supervision of Prof Peter Hutchinson and Mr Angelos Kolias. He is currently an investigator on the NIHR HTA-funded Dex-CSDH trial, a randomised controlled trial of dexamethasone vs placebo in patients with chronic subdural haematoma.
Neurosurgery; Anything to do with the inflammatory components of brain injury; Brain tumours and cerebrovascular disease
Dr. Jiu Chen is currently the committee member and secretary of China council for the promotion of health care international exchange- Cognitive Impairment Branch, and Department of Neurology in Affiliated ZhongDa Hospital of southeast university. He received his MD in 2013 from the Fourth Military Medical University in 2013 and Ph.D degree in 2017 from the Medical School of Southeast University. He had neuroimaging research training as visiting scholar at Medical College of Wisconsin in 2016, USA. He engaged in the research of the pathogenesis of subjects (late-life depression and mild cognitive impairment) at high risk to Alzheimer’s disease and developing prognostic model for predicting MCI-to-AD progression by using the multi-modal MRI and event related potential (ERP) approaches.
Neuropsychiatric Disorder (MCI: Mild cognitive impairment, AD: Alzheimer Disease); Mental Disease (Depression, Schizophrenia); Functional magnetic resonance imaging (fMRI); Event related potential (ERP); Neuroimaging; Cognitive Neuropsychology; Cognitive Neuroscience
1. Baosteel Awards in 2016;
2. National scholarship for graduate students in 2016;
3. The 3rd Award for Science and technology progress of in Shaanxi province in 2016. (Ranking No. 5);
4. A scholarship under the State Scholarship Fund in 2015;
5. National scholarship for graduate students in 2015;
6. Outstanding graduate student of Southeast University in 2015;
7. Outstanding Conference Speech Paper Award, the 12th annual Basic and Clinical Psychiatry Conference of the Chinese Society of Neuroscience and Psychiatry (CSNP) in 2015, Taiyuan;
8. Outstanding Paper Award, 4th National Academic Meeting of Dementia and Cognitive Impairment in 2015, Beijing;
9. The 2ndAward for Science and technology progress of Henan province in 2014. (Ranking No. 4);
10. Top Articles In Outstanding S&T Journal Of China, Frontrunner 5000 in 2013;
11. Outstanding Paper 1st Award, Shaanxi Annual Meeting of Psychiatry and Mental Health in 2012;
12. Outstanding Paper 2nd Award, Shaanxi Annual Meeting of Psychiatry and Mental Health in 2011.
Dr. Xingyong Chen graduated from Sun Yat-Sen University and got MD and PhD of neurology, and he is currently associate professor of Fujian Medical University. He works in department of neurology, Fujian Provincial Hospital, Fujian Medical University. He devotes himself to basic and clinical researches of stroke and neuroinflammation and neurodegenaration.
Cerebrovascular disease; Neuroinflammation; Neurodegenaration
Till now, Dr. Xingyong Chen has published several high-quality articles about his research areas.
Dr. Yan Chen is currently associate professor of Huashan Hospital affiliated to Fudan University. She graduated from Shanghai Medical University in 1996. Subsequently, she worked as resident in department of neurology in Huashan hospital. She got MD and PhD of neurology in Fudan University. Her Clinic practice and research mainly focused on Motor Neuron Disease and dystonia.
Clinic practice and research mainly focused on Neurodegeneration disease, such as Motor Neuron Disease, Parkinson disease, dystonia.
Till now, Dr. Yan Chen has published several high-quality articles about his research areas.
Prof. Chen is Professor with tenure in the Neuroscience Center of Excellence, Louisiana State University Health Sciences Center. He graduated from Nanjing University in 1983 and continued his training in Physiology from Zhejiang University School of Medicine. Dr. Chen received his PhD degree in Physiology in 1993 from Tulane University, New Orleans, USA.
Neuroscience; Neuroinflammation; Synaptic plasticity; Neurodegenerative diseases; Alzheimer’s disease; Traumatic brain injury; Endocannabinoids; COX-2, Learning and memory
Till now, Prof. Chu Chen has published 60 high-quality articles about his research areas.
Neuroinflammation, CNS disorders such as Parkinson’s disease, HIV-dementia and mood/behavior disorders, inflammatory signaling in astrocytes and microglia and modulation of these signaling events by drugs of abuse and other pharmacologic agents
Dr. Ginsberg’s editorial responsibilities include serving as Academic Editor for PLoS One and Associate Editor for Translational Neuroscience. Steve also currently serves on the Editorial Board of 8 journals, and acted as Guest Editor/Section Editor for 3 journal issues.
Dr. Ginsberg sits on Advisory Boards for the Autism Tissue Program (ATP) tissue advisory board (TAB) and the Rett syndrome International Rett Syndrome Foundation (IRSF). Dr. Ginsberg is the Chairman of the Institutional Animal Care and Use Committee (IACUC) at the Nathan Kline Institute (NKI). Steve is a member of the Department of Psychiatry Appointments and Promotions Committee (DAPC) at the New York University Langone Medical Center (NYULMC), and is part of the Center for Cognitive Neurology at NYULMC.
Anatomy and histology; Pathology; Genetics; Diet therapy
Dr. Konstantin Balashov, MD, PhD, FAAN, is a Professor of Neurology at Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ. He sees patients at the Robert Wood Johnson Center for Multiple Sclerosis, is actively involved in clinical trials and research on multiple sclerosis, and teaches medical students and neurology residents. He is board-certified in both Neurology and Neuroimaging.
Dr. Balashov received his MD and PhD degrees from the Russian State Medical University and Russian Academy of Medical Sciences, Moscow. He graduated from the Neurology Residency Program as Chief Resident at the New Jersey Neuroscience Institute in Edison, NJ and completed fellowship training in multiple sclerosis/neuroimmunology at Harvard Medical School under the mentorship of Dr. Howard Weiner.
Dr Balashov’s clinical research projects have been funded by the National Institutes of Health, National Multiple Sclerosis Society, and other research foundations. He is the author of more than 50 original papers and reviews published in academic journals such as Proceedings of the National Academy of Sciences USA; Annals of Neurology; Neurology, and Multiple Sclerosis Journal.
Till now, Dr. Konstantin Balashov has published more than 50 high-quality articles about his research areas.
Neurology common diseases such as cerebrovascular disease, central nervous system infection, epilepsy, dementia, dizziness and neurologist difficulty of diagnosis and treatment of diseases such as the treatment of critically ill patients; Central nervous system infection, and cerebrospinal fluid cytology and cognitive dysfunction and dementia research work
Dr. Vicente Felipo is Director of the Laboratory of Neurobiology and of the Program on Neuroinflammation and Neurological Impairment of the Centro de Investigacion Principe Felipe in Valencia (Spain). He has 30 years of experience in the research on the mechanisms, diagnosis and treatment of the neurological alteration in hyperammonemia, hepatic encephalopathy, by exposure to food and environmental contaminants and in other pathological situations. Vicente Felipo has authored more than 270 manuscripts, 3 patents, co-edited 7 books, organized more than 20 International Symposia and directed more than 20 doctoral theses. He has been first Secretary of the International Society for Hepatic Encephalopathy and member of different national and international Committees.
Neurobiology; neurotransmission; Neuroinflammation; Hyperammonemia; Hepatic encephalopathy; Cognitive function; Learning and memory; Motor coordination; GABAergic neurotransmission; Glutamatergic neurotransmission; NMDA receptors; AMPA receptors; GABA transporters
Till now, Dr. Vicente Felipo has published 290 high-quality articles about his research areas.
Cellular and molecular neuroscience
Dr. Yara Dadalti Fragoso is a Neurologist with further Master and Doctor degrees, areas of expertise concentrated on demyelinating diseases and headaches.
At present I’m Head of the Department of Neurology in Universidade Metropolitana de Santos, SP, Brazil and I coordinate Brazilian study groups on clinical, epidemiological and therapeutic aspects of a variety of neurological diseases.
Prospective database on pregnancy and multiple sclerosis; Treatment of headache and epilepsy in children and adolescents; Prospective database of pharmacovigilance on new drugs for the treatment of MS; Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents
Till now, Dr. Yara Dadalti Fragoso has published 85 high-quality articles about his research areas.
Blood-CNS barrier; Cell transplantation; Development; Human umbilical cord blood; Immune system; Inflammation; Neurodegenerative diseases; Regeneration; Spinal cord pathology; Stem Cells
All kinds of cerebral tumor, especially for the microscopic minimally invasive surgery in modern neurosurgery and postoperative comprehensive treatment of meningioma, malignant meningioma, multiple recurrent meningioma and meningeal sarcoma, hemangiopericytoma, skull base tumor, tumors in Saddle area, schwannoma, glioma and hydrocephalus, cerebral trauma, cerebral hemorrhage in important functional areas.
Dr. Sara G.M. Piccirillo graduated at the University of Milan (Italy) in Medical Biotechnology in 2003. She gained a PhD in Translational and Molecular Medicine in 2008 at the University of Milan-Bicocca and worked as Research Associate at the Department of Clinical Neurosciences of Cambridge University (UK) in 2010-2016. During this time, she was awarded a Marie Curie Intra-European Fellowship and in February 2011 she was elected Research Fellow of Hughes Hall, the oldest graduate college of the University of Cambridge. In 2014 she has received an Honorary Master Degree from the same University.
In 2016 she has been awarded a CRUK New investigator Research Award to launch her independent career and in the same year she has joined UT Southwestern Medical Center in Dallas (Texas) as Faculty Member in the Department of Internal Medicine.
In total, she has co-authored 25 scientific articles and reviews and 3 book chapters. In the last years, she has acted as reviewer for more than 10 international peer-review journals. She is Editorial Board Member of Neuroimmunology and Neuroinflammation since 2013.
Neural stem cells and brain tumors; Brain tumours and cancer stem cells of the brain with a focus on intra-tumour heterogeneity and phenotypic and molecular characterization of gliomas
2016 New Investigator Research Award granted by Cancer Research UK;
2014 Master of Arts (Honorary), Hughes Hall College, University of Cambridge;
2011–2016 Research Fellow at Hughes Hall College, Cambridge, UK;
2011–2013 Marie Curie Intra-European Fellowship For Career Development by the European Commission under the Seventh Framework Programme;
2010 Young Investigator Award 2010 by British Neuro-Oncology Society (BNOS) and Brain Tumour UK;
2007 Best Young Italian Researcher 2007-Premio Sapio award granted by SAPIO group;
2005 Translational Research Excellence Award by Brain Tumour UK.
Dr. Elena Grebenciucova is a native of Republic of Moldova, who moved to the United States at the age of 16.
She completed her medical education at East Carolina University, her neurology residency at the University of Chicago, and is currently a neuro-immunology fellow at the University of Pennsylvania
Multiple sclerosis；Neuromyelitis optica; Neurosarcoidosis; Transverse myelitis, Inflammatory disorders of central nervous system；CNS infections；HIV；PML
Till now, Dr. Elena Grebenciucova has published several high-quality articles about his research areas.
Autoimmune encephalitis; Anti-NMDA receptor encephalitis; Limbic encephalitis; Paraneoplastic neurological syndrome and CSF cytology
Central nervers system infectious disease and carcinomous meningeal
Chinese Medicine for the treatment and prevention of aging-associated degenerative diseases (Alzheimer’s disease and Parkinson’s Disease) and mental disorders (depression) by elucidating the molecular mechanisms of neuroprotective herbs and conducting clinical studies on the effectiveness of Chinese Medicine interventions
Prof. Tibor Hortobágyi is an academic neuropathologist, head of department and chair at the University of Debrecen, Hungary, and reader in Old Age Psychiatry at King’s College London, UK. His main research interest is neurodegeneration, cerebrovascular diseases, and traumatic brain injury and brain tumours. Tibor Hortobágyi is author on more than 130 research papers and numerous book chapters, with publications in Science and Nature Neuroscience, and editorial board member of several journals. He is councillor of the European Confederation of Neuropathological Societies (EURO-CNS) and International Society of Neuropathology (ISN). He is devoted to neuropathology teaching and is Chairman of the Board of Examiners of the European Neuropathology Exam (EFN) and Advisor at the International Department of the Royal College of Pathologists.
Neuropathology; Neurodegeneration; Cerebrovascular disease; Brain tumours
Neuropathological characterization of specials distinct subtypes of neurodegenerative diseases. Clinicopathological studies in neurodegenerative and cerebrovascular diseases and brain tumours with identification of prognostic and diagnostic markers. Characterization of a novel model of traumatic brain injury. Early detection of axonal injury in brain trauma.
Skull base; Vascular and endoscopic neurosurgery
Dr Grant Hill-Cawthorne is a medical microbiologist and the Senior Lecturer in Communicable Disease Epidemiology at the Marie Bashir Institute and School of Public Health, University of Sydney. After completing medicine and medical training at the University of Cambridge he went to Saudi Arabia where he set up a laboratory specialising in pathogen genomics. His PhD was in the use of genomics for public health microbiology and as part of this he led a large worldwide study on TB genomics as well as studies on total drug resistant TB in South Africa. His ongoing research is on the use of molecular epidemiology for public health policy, particularly focusing on emerging infections, drug resistance and the impact of mass gatherings. Grant is the unit coordinator for the communicable disease units within the Master of International Public Health and Master of Public Health. He has also co-developed a new degree: the Master of Health Security.
Infectious diseases; Microbiology, Genomics; Mass gathering medicine; Neurological infections
Dr Grant Hill-Cawthorne has rewarded Honorary Life Fellow, St. Andrew’ s College; he has applied for >$7,000,000 research funding in past 5 years and has 42 publications with the H index 11.
Prof. Chaur-Jong Hu graduated from School of Medicine, College of Medicine, Taipei Medical University (TMU) and received his Neurology training in Taipei Municipal Jen-Ai Hospital, Taipei, Taiwan. Now, he is professor and chief of neurology, TMU, also vice superintendent and the director of department of Neurology and dementia center in Shuang Ho Hospital, TMU. He has ever been a research fellow in stroke center, Washington University, St. Louis US in 2000. He devotes himself to basic and clinical researches of stroke and dementia after he came back to Taiwan. His recent researches include the connectones of fMRI in the ischemic stroke and genetic, epigenetic researches of Alzheimer disease. He is one of the founders of Taiwan Dementia Society (TDS). He joins the national collaboration stroke and dementia network, including Taiwan stroke registry, biosignature of stroke, biosignature of dementia and Taiwan stroke trial consortium and a few international clinical trials for stroke and Alzheimer disease. He has published over 100 research papers in peer-reviewed journals. He also serves as a reviewer for over 30 journals. He became a fellow of American Heart Association (FAHA) in 2015.
Stroke; Molecular neurology; Dementia
Prof. Chaur-Jong Hu has been authors or co-authors on over 130 papers in peer-reviewed journals, and served as a reviewer for over 40 peer-reviewed journals.
Neuroprotection and molecular pathogenesis of Parkinson's disease; Neuroinflammation (inflammation mediators) and Neurology (physiology and pathology)
June 2016 – to date:
Assistant Professor of Molecular Biology, Dept. BIOMETEC, University of Catania
• Neural stem cells
• Glial cells
• Parkinson’s disease
• Molecular mechanisms of CNS neuroprotection and repair
• Cell-to-cell communication via extracellular vesicles, including exosomes
• Horizontal RNA transfer (coding and non-coding)
• Nanotechnologies and Synthetic Biology
February 2011 – May 2016:
Research Fellow at the Dept. of Clinical Neurosciences, University of Cambridge.
Supervisor: Stefano Pluchino, MD, PhD
• Somatic and embryonic stem cells
• Neural stem cells
• CNS regeneration
• Molecular mechanisms of neuroprotection and cell-to-cell communication
• Extracellular vesicles (EVs), including exosomes
• Horizontal RNA transfer (coding and non-coding)
• Nanotechnologies and Synthetic Biology
January 2009 – January 2011:
Postdoctoral activity at the Dept. of Biology, University of Bologna.
Subjects of research:
• MYCN-mediated transcriptional repression in neuroblastoma
• MYC as a regulator of ABC genes in Chronic Myeloid Leukemia (CML) CD34+ hematopoietic progenitor cells
• Role of IKAROS in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL)
• Identification of novel miRNAs suppressing BCR-ABL expression in CML
Supervisor: Professor Giovanni Perini, PhD.
January 2006 – December 2008:
PhD studentship at the Dept. of Biology, University of Bologna.
• “Complexity of MYCN transcriptional function in childhood neuroblastoma.”
Supervisor: Professor Giovanni Perini, PhD.
April 2004 – December 2005:
Undergraduate/graduate studentship at the Dept. of Biology, University of Bologna.
• “Transcriptional induction of TRKA and p75NTR genes in neuroblastoma by histone deacetylase inhibitor Trichostatin A (TSA).”
Supervisor: Professor Giovanni Perini, PhD.
Molecular biology; Neurosciences
• “Brains2South” grant (Fondazione con il Sud - Bando Capitale Umano ad Alta Qualificazione 2015): “Characterization of exosomes as natural messengers of bioactive molecules in the glial-neuronal signaling in Parkinson's disease.” Principal Investigator, amount granted for 3 years: € 250,000. Dept. BIOMETEC, University of Catania.
• Emerging Research Leaders’ Development Programme (ERLDP) 2014, organised by the University of Cambridge: selected (after application).
• The Evelyn Trust 2013 grant: “Cell signalling through secreted extracellular RNAs in neuro-immune interactions.” Co-applicant, amount granted: £ 244,565. From December 2013 to November 2015. Dept. of Clinical Neurosciences, University of Cambridge
• The FEBS Long-Term Fellowship: “Mechanisms of mobile ncRNAs in stem cells.” From December 2011 to November 2013. Dept. of Clinical Neurosciences, University of Cambridge
• “Centro Interdipartimentale di Ricerca sul Cancro Giorgio Prodi” Fellowship: "Eradication of acute and chronic leukemic stem cells through interference of the self renewal mediated by the Smo Inhibitors." From January 2010 to December 2010, at the Department of Biology - University of Bologna.
• NOVARTIS Fellowship: "Identification and characterization of microRNAs that block the function of Bcr-Abl in Philadelphia positive leukemias." From January 2009 to December 2009, at the Department of Biology - University of Bologna.
• Award “Premio di Operosità”: "Transcriptional mechanisms mediated by oncoprotein N-Myc in neuroblastoma.” Granted by NOVARTIS in February 2008, at the Department of Biology - University of Bologna.
My research specialty is on determining how one can protect the central nervous system – the brain and spinal cord – against acute and chronic insults such as trauma, stroke and neurodegenerative diseases – i.e. neuroprotection – and how neural function can be restored after injury or disease – i.e. Neurorestoration, spacifically, the biological effects of these strategies, and the cellular mechanisms that underlie them employing a variety of cellular techniques particularly immunohistocytochemistry both in vitro and in vivo models.
Cellular and molecular Neuroscience:
• Biological effects of natural-occurring compounds such as non-adenine-based purines (NABPs) and Chinese herbal medicine, and their cellular and molecular mechanisms through which those natural compounds exert their effects.
• Restoration of neurological function by promoting neuroprotection and regeneration after CNS insults such as traumatic spinal cord injury, brain injury, stroke and neurodegenerative diseases.
Epilepsy; Dysmnesia; Encephalitis; Stroke
Dr. Mishra is a an MD-PhD with expertise in stroke medicine. After earning his medical doctor degree in 2005, he trained in behavioral neurology and stroke medicine at the University Hospital of Lausanne. He then went to the University of Glasgow to earn a PhD in medicine where among many clinical questions, he particularly tackled the question about the eligibility of stroke patients regarding reperfusion therapy in acute ischemic stroke patients. This was particularly about the exclusion criteria prescribed by the regulatory bodies for the use of t-PA. After earning the PhD in 2012, he moved to Stanford to study the use of perfusion imaging to select patients for endovascular stroke therapy. After about two-and-half years of post doctoral work at Stanford, Dr. Mishra spent some time at the US FDA and then moved on to do residency at Tulane. He enjoys both -- managing patients and conducting research.
Neurology; Cerebrovascular disorders
Radiculopathy; Encephalitis; Ultrasonography; Applications of ultrasound in clinical practice Neuromuscular ultrasound in immune-mediated neuropathies
Transplantation immunology; Inflammation; Inflammation mediators; Pathology; Cerebrospinal fluid
Dr. Jun-ichi Kira is Professor and Chairman in Department of Neurology, Neurological Institute, Graduate School of Medical Sciences at Kyushu University. Dr. Dr. Jun-ichi Kira’s Current Research Areas include Immunologic and genetic studies of multiple sclerosis, Clinical and immunological studies of atopic myelitis, and Biological studies of motor neuron diseasesand Alzheimer disease.
Neuroimmunological research on multiple sclerosis (Multiple sclerosis, genetic polymorphism, MRI, C-MS, OS-MS, Neuromyelitis optica, Balo disease); Cell biological research on motor neuron diseases (moter neuron disease, ALS, cytokine, growth factors, G-CSF)
Dr. Klegeris graduated with a M.Sc. in Biophysics from Moscow State Medical University. He then entered Oxford University, UK where he received his D Phil in Pharmacology in 1995. Towards the end of his studies at Oxford he became interested in inflammatory responses of the central nervous system particularly involving microglial cells. This led him to the University of British Columbia for post-doctoral studies in the Kinsmen Laboratory of Neurological Research. He was promoted to Research Associate in the Department of Psychiatry in 1999 and, in 2007 became an Assistant Professor of Pharmacology in the Department of Biology, UBC Okanagan in Kelowna , B.C. Identification of novel treatment options for neurodegenerative disease is the main research focus of the Laboratory of Cellular and Molecular Pharmacology which is currently under development. He teaches undergraduate courses in pharmacology and biochemistry.
Novel pharmacological approaches in alzheimer’s disease; Novel therapeutic approaches to neurodegenerative disease; Regulation of brain glial cell functions by extracellularly released mitochondrial transcription factor a and microparticles; Identification of novel intercellular signaling molecules of the animal central nervous system
Elucidating calcium signaling pathways that regulate fundamental physiological and pathophysiological processes; Understanding the signal transduction pathways, calcium signaling and ion channel physiology involved in the pathophysiology of different diseases such as depression, diabetes, neuroblastoma and other cancers
Parkinson's disease; Huntington's disease; Transplantation immunology; Cognitive and behavioural neuroscience; Cellular and molecular neuroscience
New approaches for the treatment of erectile dysfunction in conditions of low nitric oxide formation or bioavailability: investigation of Rho-kinase inhibitors and soluble guanylate cyclase-targeted therapies
Peripheral nerve diseases; Neuro-immunology; Clinical neurophysiology
Prof. Bin Li works in the second hospital of Hebei medical university. She graduated from Hebei medical university in 1999, and received PhD in 2008. Her research focuses on neuroimmunology.
1. Prof. Li has rewarded the Second prize of Science and Technology Progress Award of Hebei Province;
2. Prof. Li has rewarded the First prize of Hebei Medical Science and Technology Award for twice;
3. Prof. Li has rewarded the Second prize of Science and Technology Progress Award of Shijiazhuang City for twice.
Dr. Hai-Feng Li got his Bachelor degree from Shandong Medical University in 1994,and got his Doctor degree from Beijing Medical University in 1999. During Feb to Aug 2009, he was a senior visiting scholar in Karolinska Institute. During 1999-2013, he worked in the Affiliated Hospital of Medical College, Qingdao University. He is now the vice-director of Neurology department, Qilu Hospital of Shandong University (from Aug 2013).
Myasthenia gravis; CNS demyelinating diseases; Autoimmune peripheral neuropathies; Cerebrovascular disease
Dr. Hai-Feng Li has established a database of myasthenia gravis cohort of more than 1500 patients and relevant biobank since 2007, and published a series of clinical, immunological and genetics research papers based on this cohort. He also published several clinical research papers and academic communications on CNS demyelinating diseases, autoimmune peripheral neuropathies and cerebrovascular disease.
Amantadine;Neurogenic inflammation; Inflammation mediators; Encephalitis; Cerebrospinal fluid ; Etiology; Drug effects; Pathology
Biomedical image analysis; Cognitive neuroscience; Brain plasticity; MR brain imaging; Biomedical instrumentation
Immunology and molecular medicine
Dr. Liping Liu received her MD in 1993 from Medical College of Tongji University, Shanghai, China and Ph.D degree in 2002 from Medical Center of Fudan University, Shanghai, China. Subsequently, she had basic research training at National Institute of Allergy and Infectious Diseases, National Institute of Health (NIH), Dept. of Microbiology and Immunology, College of Physicians & Surgeons, Columbia University and Cleveland clinic. Then she served as Research Associate staff. Currently she is a project staff at Dept. of Neurosciences, Lerner Research Institute, Cleveland Clinic, OH, USA.
Neuroinflammation; Neurodegeneration; Neuropathic pain; Stem cell therapy for pain and regeneration; Multiple sclerosis; Chemokine; Chemokine receptors
Till now, Prof. Liping Liu has published 31 high-quality articles about his research areas.
Prof. Zhenyu Liu, received his Ph. D (with honors) in Pattern Recognition and Artificial Intelligence from the Institute of Automation, Chinese Academy of Sciences in 2014. Since then, he has been an assistant professor at the key laboratory of molecular imaging, Chinese Academy of Sciences. His mainly worked on the medical image analysis and clinical applications. He has published more than 20 research articles in peer-reviewed journals including NMR in biomedicine, Plos One, JMRI and etc.
Medical image analysis; Clinical applications
Till now, Prof. Zhenyu Liu has published several high-quality articles about his research areas.
Blood and blood components (thrombin, microNRA) in stroke and brain trauma; Cell cycle and aberrant cell cycle diseases
Neurology-neuromuscular medicine and neurophysiology; Neuromuscular disorders; Genetic disorders; Epilepsy; dementia and degenerative disorders; General neurology; Genetic and congenital disorders
Inflammation; Brain injury; Microglia; Neurodegeneration; Immunohistochemistry
Neurosurgery; Anaplastic astrocytoma (grade III glioma); Astrocytoma (grade II gliomas); Brain stem tumors; Brain tumor; CNS lymphoma; Ependymoma; Gangliomas; Gliobastoma (grade IV glioma); Medulloblastomas; Meningiomas; Metastatic cancer - brain Cancer from other organs; Oligodendroglioma; Oncology; Pilocytic astrocytoma (grade I glioma); Skull base tumors; Stereotactic biopsy
Dr. Ricky Medel serves as the Vice-Chairman and the Co-Director of Cerebrovascular, Endovascular & Skull Base Surgery at Tulane University School of Medicine, Department of Neurosurgery. He is a fellowship-trained board-certified neurosurgeon with interests in cerebrovascular disorders including aneurysms, stroke, and vascular malformations of the brain and spinal cord. Other interests include endoscopic treatment of pituitary and other skull base tumors, surgical treatment of movement disorders, and open and minimally invasive treatment of benign and malignant tumors of the brain and spine. He completed his residency at the University of Virginia, a year as the Senior Registrar in Auckland, New Zealand, and subsequently an interventional neuroradiology fellowship treating cerebrovascular disease in an open and endovascular fashion at the University of Virginia. He has active research interests in pituitary disease, stroke and vascular disorders as well as neurosurgical outcomes research.
Endovascular neurosurgery; Endoscopic treatment of pituitary and sellar tumors; Neuro-oncology; Movement disorders
Stroke; Acute management and electrophysiology (ENMG)
Autophagy; Ubiquitin proteasome system; Neurodegenerative diseases; ALS; Huntington; Parkinson's; Alzheimer's; Neuropathology; Neurobiology; Cellular and Molecular Neurobiology; Cellular quality control mechanism; Tumor suppressor genes; My principal examine awareness is “Cellular Protein Quality Control Mechanism”. I am enthralled to search the role of E3 ubiquitin ligases and molecular chaperones implicated in aberrant protein degradation linked with cell cycle regulation and cancer.
Blood - brain barrier anatomy; Brain injuries; Excitotoxicity; Heme; Inflammation mediators; Neurologic deficit; Neuronal injury; Neuronal survival; Neurons; Neuroprotection; Neurotoxic; Neurotoxicity; Pharmaceutical preparations; Postnatal; Pre-clinical; Signal transduction; Stroke; Subarachnoid hemorrhage; Therapeutic target; Toxic effect; Translational research
Neuropeptide Y-like immunoreactivity; BDNF and VEGF in the pathogenesis of stress-induced affective diseases; Brain disease, glioma
Neurogenic inflammation; Neurodegenerative disease; Microglia activation; Radiography; Radionuclide imaging; PET, MRI; Movement disorders; Deep brain stimulation
Glutamatergic receptors; Hippocampal synaptic plasticity (mainly Long Term Depression); Intracellular signalling pathway; Neuromodulation by cytokines and neuropeptides; Glia/neuronal interaction role on acute synaptic functioning; Electrophysiology; Pharmacology
Prof. George Perry (born April 12, 1953 in Lompoc, California) is a neuroscientist recognized in the field of Alzheimer's disease research particularly for his work in oxidative stress. Dr. Perry has studied at many universities and holds multiple degrees including a Bachelor of Arts degree in Zoology from the University of California Santa Barbara and a PhD in Marine Biology from the Scripps Institution of Oceanography at San Diego. He is distinguished as one of the top Alzheimer’s disease researchers by Expertscape with over 1000 publications, more than 67,000 citations (H=130), one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in free radical research. Dr. Perry is a Semmes Foundation Distinguished University Chair in Neurobiology and is an active participant in many other scientific associations. He is an elected member of the Academies of Sciences of Mexico, Portugal, and Spain. In addition, Perry is an Editor of numerous scientific journals including Journal of Alzheimer’s Disease which he founded in 1998. Today, Perry continues his love for research while working as Dean of the College of Sciences at The University of Texas at San Antonio.
Neurodegeneration; Alzheimer’s disease; Effects of oxidative stress on the disease; Effects on other neurodegenerative disorders
• Sixth-most cited author of scientific papers in Alzheimer disease in the world
• One of the top 100 most-cited scientists in neuroscience and behavior and one of the top 25 scientists in free radical research
• Cited over 67,000 times and recognized as a highly-cited researcher by Thomson Reuters Web of Science, a comprehensive resource for searching and indexing scientists by discipline
• Editor-in-chief for the Journal of Alzheimer's Disease
• Fellow of American Association for the Advancement of Sciences
• Fellow of Microscopy Society of America, and past-president of the American Association of Neuropathologists
• Member of the Dana Alliance for Brain Initiatives, among the world’s most prestigious neuroscience groups
Cerebral amyloid angiopathy (CAA); Cerebral amyloid angiopathy-related inflammation (CAA-ri); ABRA; Alzheimer's disease; Cerebrospinal fluid; Biomarkers; Anti-Amyloid autoantibody; Disease Modifying Therapies for AD; Immunization in AD
Neuroanatomy; Cellular biology; Physiology and behavior; Imaging; Immune-to-brain signaling; Neuronal substrates of altered behavior during inflammation; Inflammation and neural development
Pathophysiology of ischemic and hemorrhagic stroke as the basis for the development of novel therapeutic options for stroke patients
Experimental stroke models (transient & permanent focal cerebral ischemia, global ischemia, subarachnoid hemorrhage), methodologies to investigate cerebral microcirculation (intravital microscopy using conventional and 2-photon excitation), neurovascular stress, degeneration („vasculodegeneration“), acute and chronic stroke syndromes, pathophysiology of microcirculatory dysfunction, small vessel disease
Qi Xiao-kun is neurologist and the director of Dept. Neurology, Navy General Hospital, Bejing, who is also the director of Multidisciplinary Joint Consulting Center for Complicated Neurological Diseases. He is advisor of doctorial degree and master degree in clinical neurological specility for the Secondary Military Medical University and the Southern Medical University and the Dalian Medical University. He is a commissioner of Neurology Society in Chinese Medical Association(CMA); a commissioner of Neuroimmunology Branch of Neurology Society in CMA; a commissioner of Neuropathology Branch of Neurology Society in CMA; a director of Beijing Medical Association of CMA. He is the vice chairman of Neurology Society of the PLA Medical Science and Technology committee; the chairman of Neurology Society of Navy Medical Science and Technology Committee; the chairman of Neuroimmune and Neuromuscular Diseases Group in Neurology Society of the PLA Medical Science and Technology Committee. Now he is associate chief editor of Chinese Journal of Neuroimmunology and Neurology, an editor of Chinese Journal of Neurology, an editor of Chinese Journal of Internal Medicine ,etc. He has rich clinical experience in Neurology. More than 260 articles had been published individually. He chiefly edited three books. He got two items of Second Prize and seven items of Third Prizes of the PLA Medical Achievement.
Multiple sclerosis; Neuro myelitis opica; Myasthenia gravis; Multiple system atrophy
Prof. Majid Reza Farrokhi, now Professor of Neurosurgery, head of Shiraz Neuroscience Research Center, and Dean of Virtual School in Shiraz University of Medical Sciences, completed his Specialty Degree in Neurosurgery in 1996 and Fellowship of Spine Surgery at Innsbruck University in 2004. He has been the Vice President of Iranian Board of Examiners in Neurosurgery since 2012 and hold the position of the Chairman of Neurosurgery Department of Shiraz University of Medical Sciences in 2011-2014, Head of Fars and South of Iran AO-Spine Society in 2002-2005, and dean of Medical School, Bushehr University of Medical Sciences in 1996-1998. He has published more than 42 papers in reputed journals and 2 books and led several research projects.
Neurological disease; Neurodegenerative disease mechanisms; Inflammation; Drug discovery; Cardiovascular disease; Regenerative medicine/tissue engineering
Clinical trial with bimagrumab in IBM
Gianluca Serafini is born in Avezzano (L’Aquila), Italy, in 1978 from Italian parents. He took his degree in Medicine and Surgery at Sapienza University of Rome, becoming later psychiatrist. In 2012, he obtained his Ph.D. in Psychiatry: Early Interventions in Psychosis. From over ten years he worked as clinician and researcher at Sant’Andrea Hospital in Rome where from 2007 he is an active member of the Center for Suicide Prevention. His major research interests include neurobiology and neuroimaging of suicidal behaviour and major affective disorders, psychopharmacology, and neuroplasticity. He has been included in “2010 Marquis Who’s Who in the World”, “2011 Marquis Who’s Who in the World”, “2012 Marquis Who’s Who in the World”, “2013 Marquis Who’s Who in the World” and he is a fellow of several scientific Societies (New York Academy of Sciences, International Society for Affective Disorders, International Association for Suicide Prevention, Sociedad Española De Patología Dual, European Psychiatric Association (Secretary of the section Neuroimaging), Società Italiana di Psichiatria, Associazione Italiana Lotta allo Stigma). He is an active researcher being the author of more than 130 publications scientific contributions (author of more than 75 articles in peer reviewed international and national journals, author of approximately 40 book chapters, author of more than 20 abstract/posters in peer reviewed international journals). From 2007 he was a speaker in more than 105 national and international conferences and he is currently Editor-in-Chief of Journal of Life Medicine and Associate Editor of 2 international journals. He actually serves as reviewer for 57 peer-reviewed international journals, and he is Editorial/Advisory Board member of more than 20 peer-reviewed international journals.
Neurobiology of major neuropsychiatric disorders; Neuroimaging of major affective disorders and schizophrenia; Psychopharmacology; Amitriptyline; Neurogenic inflammation; Inflammation mediators; Anatomy and histology; Drug effects; Anatomy and histology; Diagnosis; Drug effects; Drug therapy; Epidemiology; Etiology; Physiopathology
1. 2002-2007: Department of Clinical Medicine, Shanxi Medical University 2007-2010: Department of Neurology, Second Affiliated Hospital of Soochow University.
2. 2009-2010: Doing Research into the regulation of dynein and autophagy in Zhou Jia wei’ Lab.(Development and Degeneration of Basal Ganglia), State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
3. 2010-: Stroke Unit Ward, Department of Neurology, Second Affiliated Hospital of Soochow University.
Basic and clinical research in stroke；Clinical research in neurointervention； Basic and clinical research in Parkinson’s disease seven years ago（mainly autophagy and neurodegenerative diseases）
Peng H, Zhu F, Shi J, et al. Serum Soluble Corin Is Decreased in Stroke. Stroke. 2015,46(7):1758-63. (co-first author)
Chrissa Sioka, M.D., D.Sci, is currently a Scientific Associate at the Neurosurgical Research Institute of the University of Ioannina, Greece. She received her MD in 1998 from the University of Sofia Medical School in Boulgaria, and her D.Sci from the University of Ioannina Medical School, in Greece. She is board certified in Nuclear Medicine (Greece) and has completed a six month special volunteer fellowship at the PET unit of the National Institutes of Health in Bethesda, MD, USA. Her research is focusing on molecular imaging techniques using SPECT and PET.
Imaging of brain tumors with nuclear medicine techniques; Body composition and bone mineral density in patients with multiple sclerosis; Imaging of paraneoplastic neurological syndromes
Transcriptomics in the study of pathogens and human malignancies; Human cytomegalovirus in the promotion of glioblastoma multiforme pathogenesis
Dr. Kyoungho Suk is currently a professor of Department of Pharmacology, Kyungpook National University (KNU) School of Medicine (Daegu, Korea), and the director of Brain Science & Engineering Institute of KNU. He obtained his Ph.D. in Immunology at University of California at Davis in 1994, and M.S. degree in Immunology at Cornell University in 1991. He graduated from KNU with the genetic engineering major in 1989. Dr. Suk received his postdoctoral training in the division of Rheumatology, Yale University School of Medicine, and he has been a visiting professor at Harvard Medical School between 2008 and 2009, during which he participated in large-scale experiments and systems biology approaches toward understanding of disease networks and pathways. Dr. Suk is the author of more than 200 papers published in peer-reviewed journals and holds patents on various therapeutic targets and lead compounds that could be used for the diagnosis or therapy of neuroinflammatory and neurodegenerative diseases.
For the past several years, Dr. Suk’s research focused on brain glial cells and neuroinflammation. Non-neuronal glial cells produce specific neurotransmitters and proteins under various physiological and pathological conditions to influence the survival and functions of neighboring neurons and glia in the central nervous system (CNS). Dr. Suk’s lab is interested in these proteins secreted from glial cells. A long-term goal of the lab is to identify and functionally characterize glial secretory proteins with respect to brain health and disease. Lipocalin-2, prostaglandin D2 synthase, and pentraxin-3 are a few examples of glial secretory proteins that the lab has been studying for several years. Dr. Suk’s findings based on in vitro and in vivo experiments as well as the analyses of clinical samples led to the discovery of potential biomarkers and drug targets for the acute CNS injuries and chronic disorders such as Alzheimer’s disease, vascular dementia, Parkinson’s disease, multiple sclerosis, and pathological pain. On-going works in the lab are now focused on the potential role of glial secretions in regulating the CNS functions from the physiological perspective. Glia-oriented omics approaches and large-scale experiments are also being employed to better understand a big picture of neuroinflammation and to uncover new drug targets for the devastating diseases in the CNS.
Glia; Neuroinflammation; Neurodegeneration; Functional genomics and proteomics based on large-scale experiments; Neuron-glia interaction via optogenetic control of glia
1. Lipocalin-2 as a therapeutic target for brain injury: An astrocentric perspective. Prog Neurobiol. 2016 Sep;144:158-72.
2. A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation. Nat Chem Biol. 2014 Dec;10(12):1055-60.
3. RNAi-based functional selection identifies multiple cell migration regulators dependent on PI3K/PTEN/AKT pathway. Nat Commun. 2014 Oct 28;5:5217.
Prof. Hua Su received different levels of trainings at the Nanjing Medical University, Xi’an Jiaotong University and Beijing medical University. She joined the faculty at University of California, San Francisco in 1996. Currently, she is a Professor and the Associate Director for Basic Science Research at the Center for Cerebrovascular Research, Department of Anesthesia and Perioperative Care. She is an experienced vascular biologist. Her long-term research interest is to develop therapeutic strategies that can improve outcomes in patients with cerebral vascular diseases.
Ischemic stroke; Brain arteriovenous malformation; Cerebrovascular malformation
Prof. Hua Su developed the first mouse brain arterovenous malformation (AVM) models, identified novel mechanisms that are responsible for brain AVM formation and progression.
Neuroimaging of dementia using MRI, EEG, MEG and PET; Neuroimaging; Computational modelling; Dementia; In-vivo neuroimaging methods for human using (f)MRI, PET, EEG and MEG; Computational neuroscience and statistical methods
Anatomy and histology; Pathology; Physiology
Dr. Jun Tan received his Bachelors of Medicine in the Third Military Medical University, Chongqing, China in 1983. He earned his Masters of Science in human genetics at Fudan University in 1989. Three years later, he completed his Doctoral Degree in Biological Medicine. He completed postdoctoral studies in 1996 at the Department of Human Genetics/Microbiology & Immunology at the University of Michigan, Ann Arbor. In 1998 he became Assistant Professor of Psychiatry & Behavioral Medicine at USF Health - Morsani College of Medicine and was promoted to Associate Professor in 2004 and Professor/Endowed Chair in 2007. Over the past 20 years, Dr. Tan has authored more than 150 original scientific papers in prestigious national and international journals such as Science, Nature Neuroscience, Nature Medicine, Nature Commutations, EMBO J. He is the recipient of multiple grants/merit awards from the National Institute of Health, Veterans Administration and other peer reviewed funding sources totaling more than $15 million. Dr. Tan’s philosophy is that everyone on his team has a strength and that the best way to lead is to find a way to utilize those strengths together in building a concerted effort toward success.
Neurodegenerative disease; HIV-associated Dementia; Multiple sclerosis；HIV-associated Dementia; Alzheimer's Disease; Parkinson's Disease; Amyotrophic lateral sclerosis; Pick's Disease; Autoimmune disorders
Over the past 20 years, Dr. Tan has authored more than 150 original scientific papers in prestigious national and international journals such as Science, Nature Neuroscience, Nature Medicine, Nature Commutations, EMBO J.
Neuro-Oncology (brain tumors); Neurology Education
Prof. Van den Noort received his MA-degree in Social Psychology (2000) and his MA-degree in Neuropsychology (2001) from the Radboud University Nijmegen (Nijmegen, the Netherlands) and his PhD-degree in Cognitive Neuroscience (2007) from the University of Bergen (Bergen, Norway). He is regular professor at Kyung Hee University (Seoul, South Korea) and he is visiting professor at the Free University of Brussels (Brussels, Belgium). In addition, he has worked as a guest-researcher (on a Harvard visiting scholar program) at Harvard University (Graduate School of Education, Cambridge, MA, USA).
Schizophrenia; Depression; Sleep disorders; Bilingualism; Theoretical Physics; fMRI; TMS
1. The development of a human (un)conscious brain information processing theory in which physics and neuroscience can be unified.
2.Professor Van den Noort is one of the leading Discussants of the possibilities and risks of brain stimulation. [see also Science: Science. 2014 Dec 12;346(6215):1307. doi: 10.1126/science.346.6215.1307-a]
Brain pathology (neurodegeneration and cancer) and tissue histology; Brain development;
Tumor micro environment; Primary and metastatic brain tumors; Role of altered metabolism in the progression of malignant gliomas
The recently discovered role of glia cells in synapse function promises a leap forward in our understanding and treatment of many human brain disorders. However, to realize this potential, there is an urgent need for translating novel findings in established preclinical disease models to new research products and drug targets for future therapeutics. My objective is to contribute to this translational research using a combination of advanced human neuron-astrocyte coculture methods and transgenic mouse model technologies.
My research is focused on uncovering the molecular mechanisms that cause proteins (e.g. tau, synuclein, huntingtin) to misfold and aggregate in toxic forms, which are a typical pathological hallmark of neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD) and tauopathies. The protein misfolding process goes through intermediate aggregation states called oligomers which have been recently considered to be the true toxic species as they can spread through the brain, possibly seeding disease in a prion-like manner. As such, I am also interested in looking at whether/how the toxic oligomeric forms can trigger inflammation and disease progression, which in turn might open up new therapeutic approaches for neurodegenerative disorders such as PD, HD and tauopathies. I am involved in a collaboration with the NeuroStemCellRepair aimed to look at the pathology across the Parkinson’s disease and Huntington’s disease brains using high-throughput technology platforms to identify new genetic modifiers involved in the pathophysiology of these disorders.
1. 2016-present Professor, Department of Neurology, Xuanwu Hospital, Capital Medical University
2. 2012-2016 Vice president, The Sanming First Affiliated Hospital of Fujian Medical University
3. 2010-present Director, Department of Neurology, The Sanming First Affiliated Hospital of Fujian Medical University
4. 2008-present Associate Professor, Department of Neurology, Fujian Medical University
1. 1991-1996 MD degree, Department of Clinical Medicine, Gannan Medical College
2. 1999-2002 MS degree, Department of Neurology, Fujian Medical University
3. 2002-2003 Post-doctoral Fellow, Department of Medicine, Cancer Biology Division. Harvard, Institutes of Medicine, Harvard Medical School.(Boston, USA)
4. 2003-2006 Post-doctoral Fellow, Department of Medicine, Columbia University, Medical Center (New York, USA)
5. 2008-2011 PhD degree, Department of Neurology, Capital Medical University (Beijing, China)
Neurodegenerative; Neuroimmunological disorders
1. A study on the mechanisms, prediction and intervention, The First Prize for Beijing Science and Technology, 2015;
2. A study on the clinical features and genetics of multiple sclerosis, The Third Prize for the Jiangxi Science and Technology, 2011;
3. Multiple regulatory roles of Immune-related GTPase IRGM1 in multiple sclerosis and cerebral vascular diseases. The First Prize for Sanming Science and Technology.
Dr. Jia-Wei Wang has got his Bachelor degree from the Harbin Medical University, China in 1991,and for his Masters and Doctoral degree study in 2002 from Beijing Friendship Hospital, Capital Medical University. He did his postdoctoral work at John Hopkins university in 2008. Now is the director of department of neurology and medical research center, the Beijing Tongren Hospital, Capital Medical University.
Anti autoimmune encephalitis; Neuromyelitis optica; Cerebrovascular disease; Multiple sclerosis; Myasthenia gravis; Dizziness; Headache
Till now, Dr. Jia-Wei Wang has published several high-quality articles about his research areas.
Dr. Wang obtained his Ph.D. in Pharmaceutical Sciences with Distinction from the University of British Columbia in Vancouver in 1989. He is internationally recognized for his original contributions to the fields of CNS disorders-linked proteolytic enzymes, neuroproteomics and disease biomarker discovery. He joined Parke-Davis Pharmaceutical Research (Ann Arbor, MI) in 1991, and following the company's merger with Pfizer Inc. (2000), he became Group Leader of CNS Therapeutics/CNS new targets team. He also co-chaired the Far East Scientific Opportunity Team. In 2002, he became Associate Professor of Psychiatry at the University of Florida (Gainesville, FL), Associate Director of the Center for Traumatic Brain Injury Studies and Director of the Center of Neuroproteomics and Biomarkers Research. In 2002, he co-founded Banyan Biomarkers Inc. (Alachua, Florida). In 2007, he transitioned to Banyan as full-time Chief Scientific Officer and the Center Director of the Center of Innovative Research. In 2011, he rejoined the University of Florida McKnight Brain Institute as Executive Director of the Center of Neuroproteomics and Biomarkers Research / Chief - Translational Research & Associate Professor of Psychiatry and Neuroscience and to rededicate himself to basic and translational research. He is also Chair Professor of the Taipei Medical University. Dr. Wang published more than 200 peer-reviewed papers, reviews and book chapters and co-authored eight US patents. He co-edited four books on proteases, neuroproteomics and biomarkers for CNS disorders. He also serves on five international journal’s Editorial Board. Dr. Wang was Past President and is current Council member of the National Neurotrauma Society (USA).
Neuro-Proteomics; CNS Injury; Neurodegeneration; Substance abuse research; Post-translational modification (Protease / Protein Kinase) research; Biomarkers; Diagnostics and Therapeutic development
Neurology; Stroke and dementia; Alzheimer's disease
Stroke; Neural stem cells; Neural stem cells and neural regeneration
Dr. Sara Xapelli is an investigator at Instituto de Medicina Molecular. For her PhD Sara was involved in the research of receptor-mediated mechanisms of neuroprotection and anticonvulsant properties of neuropeptide Y. During her postdoctoral studies, Sara has been interested in the role of endocannabinoids in neurogenesis and oligodendrogenesis and their relevance in both the intact and damaged brain. Currently, she is the leader investigator of several research projects aiming at finding modulators of neurogenesis and oligodendrogenesis derived from neural stem cells.
Neural stem cells; Neurodegenerative disorders; Neuroprotection; Neurogenesis; Oligodendrogenesis
Till now, Dr. Sara Xapelli has published 25 high-quality articles about his research areas.
The computing method of human brain connectomics; The application of human brain connectomics in neuropsychiatric disorders; The development of analysis and visualization software for human brain connectomics
Myasthenia Gravis; Genetic study; Translocation medicine
2005-2008 Resident in Neurology, Beijing Friendship Hospital, Capital Medical University
2008-2010 Fellow in Neuroimmunology, Beijing Friendship Hospital, Capital Medical University
2010-2012 Attending physician, Department of Neurology, Beijing Friendship Hospital, Capital Medical University
2012-2014 Associate Professor, Department of Neurology, Beijing Friendship Hospital, Capital Medical University
2013-2014 Visiting Scholar, Department of Neurology, The George Washington University
2014-present Scientist, Department of Neurology, The George Washington University
Myasthenia Gravis; Genetic study; Translocation medicine
1. Identify the variations in glucocorticoid receptor (GR) gene which are associated with the response to glucocorticoid in patients with myasthenia gravis (MG).
2. Identify the increase of GRβ in peripheral blood mononuclear cell (PBMC) is associated with bad response to glucocorticoid in patients with MG.
3. Identify the predisposing genes in HLA region of patients with MG.
1. Transplant and Immunology Fellow (Director In Training), University of Chicago Medicine. 2. August 2016–Present (5 months)Greater Chicago Area, Research Assistant Professor, Loyola University Chicago. 3. December 2013–July 2016 (2 years 8 months) Research Assoicate, Hines VA Hospital/Loyola. 4. June 2008–2013 (5 years) Postdoctoral fellow, Forensic Doctor, West China University of Medical Sciences. 5. July 1996–May 2001 (4 years 11 months)Chengdu, Sichuan, China.
Neuroscience, Immunology, Hematology, Histocompatability
1. MDA Development Award 2011-2014 (Role: PI), Muscular Dystrophy Association, July 2011.
2. LRF New Investigator Award (Role: PI), Leukemia Research Foundation, July 2014.
3. PepsiCo research competition finalist, November 2011.
4. Young Investigator’s Educational Enhancement (YIEE)” travel award, American Society of Neurochemistry, 2012.
5. Arthur J. Schmitt Dissertation Fellowship Award, Loyola University Chicago, 2007.
6. Graduate Travel Award, Society for Neuroscience, 2007.
7. Winner of Graduate Student Symposium, Chicago Chapter Society for Neuroscience, 2007.
8. 3rd Place, St. Albert’s Day Research Presentation, Loyola University Chicago 2007.
9. Outstanding Graduate of University, West China University of Medical Sciences, June 1996.
10. Outstanding Student Fellowship of University, West China University of Medical Sciences, 1993-1995.
11. Travel Award, Chicago Association for Research and Education in Science 2013.
12. 3rd place, Research Poster Competition, Hines VA Hospital, 2011.
13. Creator of gene ID cardFebruary,2001.
14. China Medical Board-sponsored Young scholar, China Medical Board, 2000.
15. Outstanding Leadership and Dedication as the President of the Chinese Student and Scholar Association, Consulate General of the P. R. China in Chicago, 2004.
Neurodegenative disease; Alzheimer's disease; Vascular dementia; The interactions between genes and hormones; Epidemiological studies and RCT
Autoimmune diseases; T cell function and mechanism; Antibody-based immune therapy
1. Scientist Development Grant, AHA-0830072N;
2. 2008-2011 American Heart Association;
3. MS4a4B as a novel modulator for the cell cycle regulation in T cells;
4. Junior Faculty Travel Award, AAI, 2010;
5. Travel Award, AAI, 2008;
6. 1998 Cora Verhagen Prize, ARVO;
7. 1998 NIH Research Excellence Award;
8. 1999 Pfizer-Showell Travel Award (FASEB), the first recipient of the this Award;
9. 1998 ARVO Travel Award, ARVO;
10. 1998 Research Excellence Award, NIH, 2008.
The research of ischemic brain damage and repair molecular mechanisms; The research of stem cell differentiation for the treatment central nervous system diseases;The diagnosis of neurology diseases, especially the diagnosis and treatment of stroke, epilepsy, parkinsonism, inflammatory myeloid and muscle pathological changes, etc.
Traumatic spinal cord injury; Neuronal and glial apoptosis following traumatic spinal cord injury
Neuroimmunology; Multiple sclerosis; Immunoregulation
Dr. Yang studied on the mechanisms of cerebrovascular diseases in both basic and clinical fields. He currently developed focal angiogenesis and focal microvessel dysplasia model in rodent brain for the cerebrovascualr research. Dr. Yang is also studying on neuroimaging, neural rehabilitation, bio-materials, and medical devices for stroke therapy.
Pediatric and congenital neurosurgery
Prof. Yang Li is currently the Vice Chairman of the Department of Neurology in Tianjin Medical University General Hospital in China. She received her MD degree in 1992 from Tianjin Medical University, Nankai University and PhD degree in 2002 from the Tianjin Medical University. From 2007 to 2008, she worked as a Post-doctoral Fellow in University of Oxford in United Kingdom. She has been engaged in the clinical, teaching and scientific research of neuroimmunological diseases from 1992 till now.
Myelitis; Encephalitis; Myasthenia gravis; Demyelinating disease and the autoimmune encephalopathy
1. Shi Q, Yang L, and Shi FD. 2011. “Pathology of Multiple Sclerosis”. In Demyelinated Disease in Nervous System. People’s Health Publishing House.
2. Zhang D, Yang L. 2011. “Guillain-Barre Syndrome”. Neurosurgical Intensive Care. People’s Health Publishing House.
3.Zhang D, Yang L. 2013. “Neuromyelitis Optica”. Neurology. People’s Health Publishing House.
Papilledema; Horner syndrome; Behcet syndrome; Neuroinflammation; Inflammation mediators; Myelitis; Encephalitis; Papilledema; Horner syndrome; Behcet syndrome
Cerebral vascular diseases; Interventional; Neuroradiology; Regenerational Medicine